Publication | Closed Access
Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial.
47
Citations
0
References
2011
Year
Surgical OncologyCancer ManagementPathologyAnnual Meeting ProceedingsMetronomic ChemotherapyHigh-risk NeuroblastomaHematological MalignancyOncologyClinical OncologyNeurologyRadiation OncologyMolecular OncologyCancer ResearchFinal TextCancer TreatmentMalignant DiseaseHr-nbl1/siopen TrialMyeloablative TherapyMalignant Blood DisorderMedicine
2 The full, final text of this abstract will be available in Part II of the 2011 Annual Meeting Proceedings, distributed onsite at the Meeting on June 4, 2011, and as a supplement to the June 20, 2011, issue of Journal of Clinical Oncology.